Here are four points:
1. Prosecutors charged the hospital and two of its physician groups for billing Medicare for more units of the cancer drug Rituxan than it actually used as well as for billing Medicare and Medicaid for services at a presurgical center that other fees covered.
2. The hospital and physician group also faced charges for submitting claims to Medicare for outpatient podiatry services deemed unnecessary.
3. Boston Medical Center reported it began an audit of the Rituxan billing, repaid some of the misused funds and was going to investigate the presurgical services billing once the hospital became aware of the federal investigation.
4. In a statement, the hospital said all healthcare institutions have to regularly identify and correct billing errors, and Boston Medical Center is committed to being a “responsible financial steward” of Medicare and Medicaid.
More articles on coding & billing:
8 key thoughts on the Medicare Shared Savings Program’s 1st few years
AAFP welcomes new CMS primary care physician payment model: 5 insights
Consumer education lacking for health insurance marketplace purchases in Texas — 4 points
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.